Integra LifeSciences Holdings Corporation announced the introduction of INTEGRA Meshed Bilayer Wound Matrix, and will feature the product at the upcoming 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society Meeting. INTEGRA Meshed Bilayer Wound Matrix has received 510(k) clearance from the US FDA. The Bilayer Wound Matrix is an advanced bilayer wound management system that is designed to provide immediate wound closure. Based on company's proven collagen technology, it is designed to be used with Negative Pressure Wound Therapy (NPWT) and also allows drainage of wound exudate directly through the meshed matrix. NPWT, also known as vacuum assisted closure. It is a technique of wound closure used to promote healing in large or chronic wounds and fight infection. A vacuum is used to reduce pressure around the wound thus drawing out excess fluids and cellular wastes. The Bilayer Wound Matrix is comprised of a complex 3- dimentional porous collagen matrix and glycosaminoglycan and a semi-permeable silicone layer. The semi-permeable silicone layer controls water vapor loss and also provides a flexible, adherent covering for the wound surface. The collagen-glycosaminoglycan matrix provides a scaffold for capillary growth and cell migration. INTEGRA Meshed Bilayer Wound Matrix's many benefits include immediate wound coverage, exceptional strength and flexibility, high conformability, room temperature storage and long shelf life. The Bilayer Wound Matrix may be used for the management of traumatic and chronic wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, vascular and chronic ulcers, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds.